Orphan drugmakers focus on developing drugs for rare diseases, but unfortunately many companies in this space never become profitable. Of those that do, few are able to succeed like Alexion ...

LONDON--(BUSINESS WIRE)--Alexion, AstraZeneca Rare Disease has launched a new electronic storybook (e-book) to support children living with rare kidney disease, atypical Haemolytic Uraemic Syndrome ...

Factor D complement inhibitors companies working in the market are AstraZeneca, Alexion (a subsidiary of AstraZeneca), BioCryst, and others. ALBANY, NY, UNITED STATES, December 4, 2024 /EINPresswire / ...

The interactive fantasy e-book Revealing the Secrets of aHUSputs young children at the centre of the story as they explore and learn with their families about atypical Haemolytic Uraemic Syndrome ...

London, 22 October, 2024 – Alexion, AstraZeneca Rare Disease, has received a positive recommendation for Voydeya® (danicopan), from the National Institute for Health and Care Excellence (NICE), as an ...